RELMADA THERAPEUTICS, INC. (RLMD) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Jun-30-19	Jun-30-18	Jun-30-17	Jun-30-16
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Operating expenses:
Research and development	113.3	90.6	36.0	7.9	7.0	2.9	1.3	6.2
General and administrative	47.9	35.1	24.9	7.2	5.7	4.0	5.9	10.0
Total operating expenses	328.8	125.7	60.8	15.1	12.7	6.9	7.2	16.2
Loss from operations	-161.2	-125.7	-60.8	-15.1	-12.7	-6.9	-7.2	-16.2

Other (expenses) income:
Gain on settlement of fees	6.4
Interest/investment income, net	9.0	1.2	1.4	0.1	-0.8	-1.3	0.0	0.0
Realized (loss) gain on short-term investments	-0.6	-0.6	-0.2

Unrealized (loss) gain on short-term investments
Total other income	4.2	0.0	3.2	0.1	-4.6	-2.0	0.9	13.2
Net loss	-157.0	-125.8	-59.5	-15.0	-17.3	-9.0	-6.3	-3.0

Loss per common share – basic (in Dollars per share)	($5.30)	($7.16)	($3.81)	($1.62)	($2.74)	($0.71)	($0.52)	($0.26)

Weighted average number of common shares outstanding – basic (in Shares)	29.6	17.6	15.6	9.2	6.3	12.5	12.1	11.6